Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:5/28/2008

inical and preclinical drug development candidates and programs that have not been determined to be safe or effective in humans for any uses.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , July ... and Genective, key developer of biotech crops, today ... of new generations of insect control traits. ... to counter the realities of advancing insect resistance. ... AgBiome,s unique insect control technology with Genective,s capability ...
(Date:7/1/2015)... and BANGALORE, India , July 1, ... company that uses next generation sequencing technology to empower ... A. Storrer as chief executive officer. In his ... be responsible for all strategy, business expansion and worldwide ... has served as Strand,s chairman and CEO since its ...
(Date:7/1/2015)... 1, 2015 Isagenix International, a leading global ... Gold, three Silver, and three Bronze Stevie® Awards at ... Chicago this month.The American ... awards program in the U.S. "Winning ... in developing leaders, cultivating talent, creating a unified team, ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company ... Philadelphia, PA. , The presentation took place on Tuesday, June 16 and ... the development of APX3330 for the treatment of pancreatic cancer. A copy of ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... International Holdings, Inc. (NYSE Amex: BONE ... graft material and antimicrobial coatings for medical applications, signed ... in the U.S. and Canada of Jeil,s LeForte System. ... implants used in craniomaxillofacial procedures, including trauma and reconstruction, ...
... Nov. 27, 2011  Candelis announced today that it has ... MSFT ) whereby Candelis, ASTRA cloud-hosted suite of services ... medical images and studies to patients, Microsoft HealthVault accounts ... a personal health application platform that lets consumers gather, ...
... Led by a group at the University of Maryland ... materials research and an age-old metallurgy technique to produce ... new class of sensors and micromechanical devices controlled by ... is notable, among other things, for not using rare-earth ...
Cached Biology Technology:Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 2Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 3Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 4Candelis and Microsoft Team Up to Empower Patients 2Candelis and Microsoft Team Up to Empower Patients 3New magnetic-field-sensitive alloy could find use in novel micromechanical devices 2
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... , June 17, 2015  Synaptics Inc. ... interface solutions, today announced that Xiaomi, one of ... Synaptics ® ClearPad ® family of ... driver integrated circuits (DDICs) for its latest smartphones, ... leveraging ClearPad for full in-cell display solutions and ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... , , , WALL, ... Bulletin Board: BKYI), a leader in finger-based biometric ... of the world,s most respected security publications, named ... in the Access Control sub-category Biometrics. , (Logo: ...
... San Diego are developing new regenerative therapies for heart ... regenerative therapies for cardiovascular and other diseases are treated ... Diego on using adult stem cells to regenerate heart ... were presented this week in San Diego at the ...
... GAINESVILLE, Fla. University of Florida researchers have found ... dosage of a highly toxic, debilitating chemotherapy drug to achieve ... is needed before the therapy can be tested in patients, ... mice with established human tumors suggests that the addition of ...
Cached Biology News:BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Supportive materials will help regenerate heart tissue 2Small addition to cancer drug may make big difference 2Small addition to cancer drug may make big difference 3
MHC Volumes 1 & 2...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
... MW: 34.2kDa Formulation: 10mM HEPES, pH ... dithiothreitiol with 50% glycerol Properites: For ... Certificate of Analysis for individual lots ... followed by gel filtration and Mono-S ...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Biology Products: